SARS-CoV Nucleoprotein / NP Protein (His Tag)

1/1
Price:
Size:
Number:

SARS-CoV Nucleoprotein / NP Protein (His Tag): Product Information

Purity
> 80 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Testing in progress
Protein Construction
A DNA sequence encoding the SARS-CoV (isolate:Tor2) nucleoprotein (NP_828858.1) (Met1-Ala422) was expressed with a C-terminal polyhistidine tag.
Accession#
Expressed Host
Baculovirus-Insect Cells
Species
SARS
Predicted N Terminal
Met
Molecule Mass
The recombinant SARS-CoV nucleoprotein comprises 433 amino acids and has a predicted molecular mass of 47.5 kDa. The apparent molecular mass of the protein is approximately 47.1 kDa in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile 20 mM Tris, 500 mM NaCl, 10 % glycerol, pH 7.4.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

SARS-CoV Nucleoprotein / NP Protein (His Tag): Images

Citation List

SARS-CoV Nucleoprotein / NP Protein (His Tag): Synonyms

coronavirus NP Protein, SARS; coronavirus Nucleocapsid Protein, SARS; coronavirus Nucleoprotein Protein, SARS; cov np Protein, SARS; ncov NP Protein, SARS; novel coronavirus NP Protein, SARS; novel coronavirus Nucleocapsid Protein, SARS; novel coronavirus Nucleoprotein Protein, SARS; NP Protein, SARS; Nucleocapsid Protein, SARS; Nucleoprotein Protein, SARS

Coronavirus Nucleocapsid Background Information

Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.
References
    1. 1.Van Boheemen S, et al. (2012), MBio. 3(6):e00473-12.
    2. Bisht H. et al., 2004, Proc Natl Acad Sci. 101 (17): 6641-6.
    3. Li W. et al., 2005, Science. 309 (5742): 1864-8.
  • Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray
    Author
    De Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
    Author
    Khan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • Antibody responses to SARS-CoV-2 in patients with COVID-19
    Author
    Long, QX;Liu, BZ;Deng, HJ;Wu, GC;Deng, K;Chen, YK;
    Year
    2020
    Journal
    Nature Medicine
  • Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients
    Author
    Okba, NMA;Müller, MA;Li, W;Wang, C;GeurtsvanKessel, CH;Corman, VM;Lamers, MM;Sikkema, RS;de Bruin, E;Chandler, FD;Yazdanpanah, Y;Le Hingrat, Q;Descamps, D;Houhou-Fidouh, N;Reusken, CBEM;Bosch, BJ;Drosten, C;Koopmans, MPG;Haagmans, BL;
    Year
    2020
    Journal
    Emerging Infect. Dis.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.